Detalhe da pesquisa
1.
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey.
Mult Scler Relat Disord
; 77: 104870, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37454568
2.
The Utility of Delta-9-Tetrahydrocannibinol Therapy in a Multiple Sclerosis Patient with a Neoplastic Brain Lesion.
Eur J Case Rep Intern Med
; 8(5): 002188, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34123935
3.
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score.
J Neurol Neurosurg Psychiatry
; 78(7): 757-9, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17220286
4.
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.
J Neurol Sci
; 239(1): 95-9, 2005 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16209877
5.
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.
Mult Scler Int
; 2015: 763418, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26266049
6.
Postmarketing evidence of disease-modifying drugs in multiple sclerosis.
Neurol Sci
; 29 Suppl 2: S225-6, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18690499
7.
New natural history of interferon-beta-treated relapsing multiple sclerosis.
Ann Neurol
; 61(4): 300-6, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17444502
8.
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis.
Mult Scler
; 12(5): 578-85, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17086903
9.
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
Mult Scler
; 9(5): 451-7, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14582768